245 related articles for article (PubMed ID: 11169147)
1. Expression of p21Waf1, p27Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ: Relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status.
Oh YL; Choi JS; Song SY; Ko YH; Han BK; Nam SJ; Yang JH
Pathol Int; 2001 Feb; 51(2):94-9. PubMed ID: 11169147
[TBL] [Abstract][Full Text] [Related]
2. EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast.
Lebeau A; Unholzer A; Amann G; Kronawitter M; Bauerfeind I; Sendelhofert A; Iff A; Löhrs U
Breast Cancer Res Treat; 2003 May; 79(2):187-98. PubMed ID: 12825853
[TBL] [Abstract][Full Text] [Related]
3. Elevated levels of p27, p21 and cyclin D1 correlate with positive oestrogen and progesterone receptor status in node-negative breast carcinoma patients.
Reed W; Flørems VA; Holm R; Hannisdal E; Nesland JM
Virchows Arch; 1999 Aug; 435(2):116-24. PubMed ID: 10599310
[TBL] [Abstract][Full Text] [Related]
4. Cell cycle proteins do not predict outcome in grade I infiltrating ductal carcinoma of the breast.
Leong AC; Hanby AM; Potts HW; Tan DS; Skilton D; Ryder K; Harris WH; Liebmann RD; Barnes DM; Gillett CE
Int J Cancer; 2000 Jan; 89(1):26-31. PubMed ID: 10719727
[TBL] [Abstract][Full Text] [Related]
5. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
Ioachim E
Int J Clin Pract; 2008 Nov; 62(11):1736-43. PubMed ID: 19143860
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
[TBL] [Abstract][Full Text] [Related]
7. Multiparameter immunohistochemical analysis of the cell cycle proteins cyclin D1, Ki-67, p21WAF1, p27KIP1, and p53 in mantle cell lymphoma.
Izban KF; Alkan S; Singleton TP; Hsi ED
Arch Pathol Lab Med; 2000 Oct; 124(10):1457-62. PubMed ID: 11035575
[TBL] [Abstract][Full Text] [Related]
8. p27KIP-1, cyclin A and cyclin D1 protein expression in ductal carcinoma in situ of the breast: p27KIP-1 correlates with hormone receptor status but not with local recurrence.
Millar EK; Tran K; Marr P; Graham PH
Pathol Int; 2007 Apr; 57(4):183-9. PubMed ID: 17316413
[TBL] [Abstract][Full Text] [Related]
9. p21WAF1/Cip1 is associated with cyclin D1CCND1 expression and tubular differentiation but is independent of p53 overexpression in human breast carcinoma.
Rey MJ; Fernández PL; Jares P; Muñoz M; Nadal A; Peiró N; Nayach I; Mallofré C; Muntané J; Campo E; Estapé J; Cardesa A
J Pathol; 1998 Mar; 184(3):265-71. PubMed ID: 9614378
[TBL] [Abstract][Full Text] [Related]
10. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21(Waf1/Cip1) and p27(Kip1) in urothelial carcinoma: correlation with other cell-cycle-related proteins (Rb, p53, Ki-67 and PCNA) and clinicopathological features.
Ioachim E; Michael M; Stavropoulos NE; Kitsiou E; Hastazeris K; Salmas M; Stefanaki S; Agnantis NJ
Urol Int; 2004; 73(1):65-73. PubMed ID: 15263796
[TBL] [Abstract][Full Text] [Related]
11. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters.
Naidu R; Wahab NA; Yadav MM; Kutty MK
Oncol Rep; 2002; 9(2):409-16. PubMed ID: 11836618
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients.
Hwang TS; Han HS; Hong YC; Lee HJ; Paik NS
Pathol Int; 2003 Feb; 53(2):74-80. PubMed ID: 12588434
[TBL] [Abstract][Full Text] [Related]
13. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in 'pure' ductal carcinoma in situ of the breast.
de Roos MA; van der Vegt B; Peterse JL; Patriarca C; de Vries J; de Bock GH; Wesseling J
Histopathology; 2007 Aug; 51(2):227-38. PubMed ID: 17650217
[TBL] [Abstract][Full Text] [Related]
14. p21, p27, cyclin D1, and p53 in rectal cancer: immunohistology with prognostic significance?
Schwandner O; Bruch HP; Broll R
Int J Colorectal Dis; 2002 Jan; 17(1):11-9. PubMed ID: 12018448
[TBL] [Abstract][Full Text] [Related]
15. Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast.
Baqai T; Shousha S
Histopathology; 2003 May; 42(5):440-7. PubMed ID: 12713620
[TBL] [Abstract][Full Text] [Related]
16. High nuclear grade, frequent mitotic activity, cyclin D1 and p53 overexpression are associated with stromal invasion in mammary intracystic papillary carcinoma.
Zhang C; Zhang P; Hao J; Quddus MR; Steinhoff MM; Sung CJ
Breast J; 2005; 11(1):2-8. PubMed ID: 15647071
[TBL] [Abstract][Full Text] [Related]
17. Cyclin D1 expression in ductal carcinoma in situ, atypical ductal hyperplasia and usual ductal hyperplasia: an immunohistochemical study.
Umekita Y; Yoshida H
Pathol Int; 2000 Jul; 50(7):527-30. PubMed ID: 10886733
[TBL] [Abstract][Full Text] [Related]
18. Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation.
Pruneri G; Carboni N; Baldini L; Intini D; Colombi M; Bertolini F; Valentini S; Maisonneuve P; Viale G; Neri A
Hum Pathol; 2003 Jan; 34(1):41-7. PubMed ID: 12605365
[TBL] [Abstract][Full Text] [Related]
19. Cytologic evaluation of cyclin D1 expression in primary breast carcinoma.
Park K; Han S; Kim HY; Ko I
Cancer; 2001 Jun; 93(3):211-5. PubMed ID: 11391609
[TBL] [Abstract][Full Text] [Related]
20. Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia.
Gillett CE; Lee AH; Millis RR; Barnes DM
J Pathol; 1998 Apr; 184(4):396-400. PubMed ID: 9664905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
